The “passive” notification led to more patients with severe AS undergoing valve replacement, but more can be done still.

The recommendations are similar to those recently announced for TTVR, with the final NCD for T-TEER expected by July.

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

Disappointment over a cardiology board, an FDA approval, meeting news, and advice for practice—it’s all here this month.

The follow-up brought little surprise, with investigators pleased the risk of death/disabling stroke remained on par with ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

Experts are dismayed, disappointed, and confused, but many say this isn’t the end of cerebral embolic protection for TAVI.

LV thrombus is less of an issue now thanks to primary PCI and antithrombotics, but it still occurs in 9% of anterior MIs.

The prothrombin complex concentrate costs more than plasma, but may pay dividends by way of fewer adverse events.

Nurse-led efforts to provide patients with ongoing lifestyle advice, education, and other resources reduced MACE by 30%.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.